A detailed history of Royal Bank Of Canada transactions in Liquidia Corp stock. As of the latest transaction made, Royal Bank Of Canada holds 9,099 shares of LQDA stock, worth $96,904. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,099
Previous 9,133 0.37%
Holding current value
$96,904
Previous $109,000 17.43%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.9 - $14.11 $302 - $479
-34 Reduced 0.37%
9,099 $90,000
Q2 2024

Aug 14, 2024

BUY
$11.96 - $15.71 $77,548 - $101,863
6,484 Added 244.77%
9,133 $109,000
Q1 2024

Nov 05, 2024

SELL
$11.35 - $16.73 $73,593 - $108,477
-6,484 Reduced 71.0%
2,649 $39,000
Q1 2024

May 15, 2024

SELL
$11.35 - $16.73 $152,475 - $224,750
-13,434 Reduced 83.53%
2,649 $39,000
Q4 2023

Feb 14, 2024

BUY
$5.77 - $12.19 $46,269 - $97,751
8,019 Added 99.44%
16,083 $193,000
Q3 2023

Nov 14, 2023

BUY
$6.27 - $8.15 $18,835 - $24,482
3,004 Added 59.37%
8,064 $51,000
Q2 2023

Aug 14, 2023

BUY
$6.63 - $9.9 $5,728 - $8,553
864 Added 20.59%
5,060 $39,000
Q1 2023

May 15, 2023

SELL
$5.72 - $7.91 $157,242 - $217,445
-27,490 Reduced 86.76%
4,196 $28,000
Q4 2022

Feb 14, 2023

BUY
$4.68 - $6.54 $5,007 - $6,997
1,070 Added 3.49%
31,686 $201,000
Q3 2022

Nov 14, 2022

BUY
$3.73 - $8.39 $884 - $1,988
237 Added 0.78%
30,616 $166,000
Q2 2022

Aug 15, 2022

SELL
$3.37 - $7.55 $97,106 - $217,553
-28,815 Reduced 48.68%
30,379 $132,000
Q1 2022

May 16, 2022

BUY
$5.14 - $7.38 $179,935 - $258,351
35,007 Added 144.73%
59,194 $425,000
Q4 2021

Feb 14, 2022

BUY
$2.71 - $5.17 $65,546 - $125,046
24,187 New
24,187 $117,000
Q3 2021

Nov 15, 2021

SELL
$2.28 - $2.95 $3,755 - $4,858
-1,647 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$2.51 - $3.11 $4,133 - $5,122
1,647 New
1,647 $5,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $685M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.